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ABSTRACT 
While major improvements have been made in targeting primary tumor growth, metastasis and 
combating cancer spread remain an enigma. We recently identified a systemic inflammatory 
cascade involving IL17-producing γδ T cells and neutrophils that advance breast cancer 
metastasis. These data provide insights into how immune cells promote cancer spread. 
 
ARTICLE 
When deleterious events happen on the planet Earth whether natural or human-made, they 
often have far-reaching consequences beyond the local site of injury. Take the 2012 Fukushima 
power plant nuclear meltdown in Japan, and the 2010 eruption of Iceland's Eyjafjallajökull 
volcano for example. Low levels of radioactive cesium from Fukushima almost traveled to the 
California coast, around 8600 km away. The ash from Iceland, which disrupted European and 
trans-Atlantic flights for weeks, floated across the European continent and even as far as Russia. 
Like these events, localized tumors within an organism reach far beyond their boundaries to 
affect distant organs and evoke systemic responses. Confined tumors induce these long 
distance changes that consequently create the right conditions for cultivation of tumor growth 
and metastasis.1  
 Recently, our lab unraveled a mechanism in the K14cre;Cdh1F/F;Trp53F/F (KEP) mouse 
model by which mammary tumors systemically reshape the host immune system to support 
metastasis.2 We showed that IL17-producing γδ T cells, activated by mammary tumor-derived 
IL1β, drive systemic expansion and polarization of neutrophils. The far-reaching accumulation of 
neutrophils and their reeducation establishes an organism-wide immunosuppressive 
environment that blocks the anti-tumor activity of CD8+ T cells and increases the efficiency of 
mammary cancer metastasis (Figure 1).2 
Neutrophils suppress T cell activation by upregulation of iNOS,2 placing them under the 
myeloid-derived suppressor cell (MDSC) umbrella. These neutrophils express CD11b, Ly6G and 
Ly6C, but lack expression of F4/80 and CCR2, which distinguishes them from monocytes, 
macrophages and dendritic cells. However, neutrophils from tumor-bearing KEP mice contain 
both mature and immature populations, based on nuclear morphological analysis and 
expression of the hematopoietic stem cell marker, cKIT, by a fraction of the population. As 
expected, the depletion of these neutrophils unleashes the functions of CD8+ T cells and 
decreases metastasis formation. Importantly, the depletion of CD8+ T cells alone does not 
increase metastasis.2 These data indicate that CD8+ T cells are completely indolent in the KEP 
model until the neutrophil-generated immunosuppressive barrier is broken. 
We found that IL17-induced G-CSF elicits the suppressive functions of neutrophils.2 
TGFβ has also been proposed to regulate neutrophil polarization;3 although, in the KEP model, 
TGFβ doesn’t seem to be as important as G-CSF. TGFβ levels are equivalent in tumor-bearing 
KEP;Rag1—/— mice and KEP mice, while IL17 levels, G-CSF levels and iNOS expression in 
neutrophils from KEP;Rag1—/— mice is reduced. As a result, TGFβ is more likely acting on γδ T 
cells or another population rather than neutrophils in our model. 
Many of our findings are strikingly similar to other observations made about the pre-
metastatic niche.4, 5 First, we found that neutrophils are most important during the early steps of 
the metastatic cascade.2 Second, neutrophils in our model share several of the phenotypic 
characteristics with other cells implicated in the pre-metastatic niche, such as expression of 
VEGFR1 and cKIT.4, 5 Third, in addition to iNOS, neutrophils in KEP mice upregulate expression 
of Bv8/Prok2, S100a8 and S100a9 – three genes known to participate in establishment of the 
pre-metastatic niche.4, 5 However, there is one major difference between our data and that of 
others: neutrophils are not restricted to metastasis-specific organs, like lungs or lymph nodes, 
they accumulate in every organ throughout the whole mouse. This almost rules out the 
possibility that neutrophils drive organ-specific tropism towards the lung and draining lymph 
node. At the same time, these observations raise the question of whether a pre-metastatic niche 
exists in the KEP model. Is there another mechanism at play that actively directs mammary 
cancer cells to pre-determined locations? Are other (immune) cells responsible? These 
questions remain to be answered. 
 Upstream of neutrophil expansion and polarization, γδ T cells produce IL17 to increase 
systemic G-CSF levels. All three components – γδ T cells, IL17 and G-CSF – are required for 
neutrophil expansion, since their depletion or neutralization prevents this cascade. The depletion 
or genetic knockout of γδ T cells in our spontaneous metastasis model also decreases multi-
organ metastasis in an analogous fashion to neutrophil depletion. However, there is still one 
missing piece of the puzzle: what cell type is activated by IL17 to upregulate G-CSF and where 
does this occur? Previous studies have shown that tumor-associated fibroblasts produce G-CSF 
in response to IL17.6 It would be interesting to assess whether the same is true in the KEP 
model.  
Together, our mechanistic data in mouse models and the clinical data of others indicate 
that γδ T cells and neutrophils join forces to expedite breast cancer metastasis.7-9 So how do we 
identify patients that may be most susceptible to this inflammatory cascade? As higher 
neutrophil-to-lymphocyte ratios are associated with worsened metastasis-specific survival,7 γδ T 
cell and neutrophil therapies may be effective in these patients. Determining which mutational 
signatures in primary tumors are correlated with systemic inflammation may also be beneficial 
for future stratification. How should γδ T cells and neutrophils be targeted in breast cancer 
patients without causing major toxicities or increased infections? One strategy may be to reverse 
the polarization of these cells as a means to down-regulate their immunosuppressive and pro-
metastatic abilities, without loosing other anti-infectious properties. Bisphosphonates are one 
such way to alter γδ T cell behavior,10 and IL17 stands out as an ideal upstream candidate to 
modify neutrophil phenotype. One IL17 inhibitor was recently approved for use in patients with 
psoriasis. Our data provide several potential avenues to target systemic inflammation and 
combat metastasis – the primary cause of cancer-related deaths. 
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FIGURE LEGEND 
Figure 1. Mammary tumor-activated γδ T cells educate immunosuppressive neutrophils to 
advance metastasis. IL1β released into the circulation by mammary tumors activates γδ T cells 
to produce IL17. An unknown cell type responds to IL17 by upregulating G-CSF, causing 
neutrophil expansion and polarization towards an immunosuppressive phenotype. Through an 
iNOS-dependent mechanism, neutrophils dampen CD8+ T cell killer functions so that 
disseminated cancer cells are protected from attack. 
